The Outcome of Induction Therapy With Monoclonal Antibodies in Kidney Transplantation Among Iranian Patients: A Prospective Study

Transplantation Proceedings

Volumn 41, Issue 7, 2009, Pages 2768-2771

  Naderi, G H ^a   Mehraban, D ^a   Ganji, M R ^a   Jafarpouriani, M ^a   Latif, A H ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN; DACLIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SALVAGE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRAN; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; NEPHRECTOMY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CADAVER; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; IRAN; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; NEPHRECTOMY; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; TISSUE DONORS;

EID: 70149096870     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.180     Document Type: Article

References (21)

1. Lin M., Ming A., and Zhao M. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study. Clin Transplant 20 (2006) 325
2. Wissing K.M., Fomegné G., Broeders N., et al. HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies. Transplantation 85 (2008) 411
3. Vincenti F. Current use and future trends in induction therapy. Saudi J Kidney Dis Transplant 16 (2005) 506
4. Sheashaa H.A., Bakr M.A., Fouda M.A., et al. Is it worth using daclizumab induction therapy with mycophenolate mofetil-based immunosuppressive regimens in live related donor kidney transplantation?. A long-term follow up. Int Urol Nephrol 39 (2007) 317
5. Sheashaa H.A., Bakr M.A., Ismail A.M., et al. Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study. Clin Exp Nephrol 12 (2008) 376
6. Rainiene T., Dobrovolskiene R., Dainys B., et al. Clinical effect of induction therapy with monoclonal antibodies after deceased-donor kidney transplantation (an experience from Vilnius Center). Medicina (Kaunas) 43 Suppl 1 (2007) 109
7. Morris J.A., Hanson J.E., Steffen B.J., et al. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. Clin Transplant 19 (2005) 340
8. Al Najjar A., Etienne I., Le Pogamp P., et al. Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation. Transplant Proc 38 (2006) 2298
9. Ji S.M., Li L.S., Cheng Z., et al. A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience. Transplant Proc 39 (2007) 1396
10. Cho W.H., Lee H.J., Kim H.T., et al. Basiliximab does not reduce the early rejection incidence in high-risk kidney recipients under tacrolimus-based immunosuppression. Transplant Proc 40 (2008) 2234
11. Ramirez C.B., and Marino I.R. The role of basiliximab induction therapy in organ transplantation. Expert Opin Biol Ther 7 (2007) 137
12. Abramowicz D., Vanrenterghem Y., Squifflet J.P., et al. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial. Clin Transplant 19 (2005) 475
13. Webster A.C., Playford E.G., Higgins G., et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 77 (2004) 166
14. Adu D., Cockwell P., Ives N.J., et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 326 (2003) 789
15. Jorge S., Guerra J., Silva S., et al. Induction immunosuppressive therapy in renal transplantation: does basiliximab make the difference?. Transplant Proc 40 (2008) 693
16. Cheung C.Y., Liu Y.L., Wong K.M., et al. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?. Nephrology (Carlton) 13 (2008) 251
17. Kandus A., Grego K., Arnol M., et al. Effective immunoprophylaxis with basiliximab plus triple therapy in renal transplantation: five-year single-center experience. Transplant Proc 38 (2006) 2853
18. Knight R.J., Kerman R.H., Schoenberg L., et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Transplantation 78 (2004) 904
19. Stratta R.J., Alloway R.R., Lo A., et al. A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years. Transplant Proc 37 (2005) 3531
20. Pham K., Kraft K., Thielke J., et al. Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection. Transplant Proc 37 (2005) 899
21. Vega O., Cárdenas G., Correa-Rotter R., et al. Basiliximab vs. limited-dose daclizumab (2 mg/kg) administered in single or two separated doses in kidney transplantation. Rev Invest Clin 60 (2008) 82